Influenza is an important disease in children. In April 2009, human infections caused by a novel swine H1N1 virus were reported in Mexico, followed by a pandemic. As of 14 March 2010, more than 213 countries and overseas territories or communities have reported laboratory-confirmed cases of pandemic influenza H1N1 2009, including at least 16,813 deaths. This influenza pandemic is unique in many respects. Large outbreaks occurred outside the usual season for influenza infection. The virus also caused severe illnesses and deaths in younger people, with many deaths caused by severe pneumonia. A comprehensive approach to pandemic control has been launched, including infection control interventions, antiviral drugs and vaccines. Vaccination is the most efficient way to control morbidity and mortality resulting from influenza infections in humans. For the first time, an influenza vaccine against a pandemic strain became available before the winter. However, the initially smooth influenza vaccination program was disturbed by the fear of possible adverse events following immunization. In Taiwan, mistrust of the influenza vaccination has also caused significant social impacts towards the end of 2009. Lessons learned from this pandemic influenza H1N1 2009 might help health authorities and physicians shape their preparedness for the next pandemic. The pandemic (H1N1) 2009 is unique in many respects. It had taken less than 6 weeks since the first notification to the WHO of the new H1N1 infections in humans and the subsequent spread of the virus throughout the world. In contrast, past pandemics have taken about six months to become established; this is probably a reflection of our increasing global mobility. 3 Large outbreaks occurred outside the usual season for influenza. The virus also caused severe illness and deaths in younger people, with many deaths caused by severe pneumonia. Table 1 4 illustrates the major events that happened during the 2009 H1N1 influenza pandemic in Taiwan.
Historical Review of Pandemic Influenza

Influenza Pandemics in History
The influenza virus derived its name in the 14 th − 15 th Century when a Florentine family used the word "influence" to suggest an unusual conjunction of planets at times of cough, cold or fever epidemics. The word "influenza" was thus derived as a description for the epidemics due to "influences" or "ab occulta coeli influential". 5 Our world has been affected by influenza epidemics and pandemics for many centuries. The three previous influenza pandemics in the 20 th century, A/H1N1 from 1918 to 1919 ("Spanish flu"), A/H2N2 from 1957 to 1963 ("Asian flu"), and A/H3N2 from 1968 to 1970 ("Hong Kong flu"), were characterized by a shift in the virus subtype, a shift of the highest mortality to younger populations, successive pandemic waves, higher transmissibility than seasonal influenza, and different impacts in different geographic regions. 6 In 1918, the influenza epidemic also swept through all 12 administrative districts of Taiwan in less than a month. The total estimated number of excess deaths was 51,048. Given the average Taiwan population size during 1918−1920, the percentage of excess deaths was about 1.38%. 
Discovery and Biological
Characteristics of Influenza A Virus Discovery of the first Oseltamivir-resistant pandemic influenza A (H1N1) virus strain in Taiwan  Nov 1 People affected by Typhoon Morakot received first batch of influenza A (H1N1) vaccine Nov 5
Influenza A (H1N1) infection in pigs on a pig farm in Taitung  Nov 16 Mass immunization campaign against pandemic (H1N1) at elementary schools began Nov 23
Immunization of junior high school students began Nov 30
Immunization of senior high school students began Dec 12
Nationwide H1N1 vaccination campaign began *325 means that "within 3 days, when 2 or more students in the same class are diagnosed to have contracted influenza, a class is suspended for 5 days, including weekends and holidays". CECC = Central Epidemic Command Center.
other subtype strains. As a result of changes in the surface glycoproteins of the virus, de vastating epidemics and pandemics have occurred in humans; in addition, major epizootics have been reported in poultry, pigs, horses, seals and camels. influenza has varied from 10% to 70%, and is directly related to the amount of virus in the specimen but inversely related to the threshold cycle value of the test. 11 Rapid screening tests for influenza may detect the presence of antigen from either influenza A or influenza B in respiratory specimens. Although rapid screening tests have a high specificity (> 95%), their sensitivities are variable when compared with RT-PCR. A negative result from a screening test does not rule out influenza virus infection. 12 Screening tests cannot distinguish H1N1 novel influenza from seasonal H1N1 or H3N2 influenza A viruses.
Treatment of Influenza Infection
The neuraminidase enzyme is responsible for cleaving sialic acid residues on newly formed virions; this is essential for the release of recently formed viral particles from the infected cell. Thus, the enzyme helps with the spread of the virus to other cells. Neuraminidase inhibitors block the enzyme's ability to cleave sialic acid residues on the surface of the infected cell, thereby inhibiting the release of progeny virions from the infected cells and reducing infectivity. 13 To date, with few exceptions, the 2009 H1N1 virus remains susceptible to neuraminidase inhibitors (oseltamivir and zanamivir) and resistant to the adamantanes (amantadine and rimantadine).
14 Antiviral treatment is recommended for all hospitalized patients with confirmed, probable, or suspected 2009 H1N1 infection and those at high risk for complications. 15 The first oseltamivir-resistant pandemic influenza A (H1N1) virus strain in Taiwan was isolated from a 20-year-old male in October, 2009. 16 The virus isolated from the case prior to oseltamivir treatment was sensitive to oseltamivir. However, the virus isolated three days after initiation of treatment displayed a mutation involving the substitution of a histidine for tyrosine at position 275 (H275Y), which was resistant to oseltamivir, de monstrating mutation of the virus after the treatment administration. 16 Oseltamivir treatment was not associated with statistically significant reduction in the duration of viral shedding, 17 thereby proving ineffective in preventing viral spread in community.
Influenza Vaccines
Vaccination is the most effective measure for preventing influenza-associated morbidity and mortality. The first experiments on the attempted immu nization of animals were made in the US by Francis and Magill in 1935 18 and in England by Andrews and Smith in 1937. 19 In the 1940s, the virus could be propagated in embryonated hen's eggs by researchers. The first vaccines against influenza were formaldehyde-inactivated whole-virus vaccines. They were developed by the US armed services and made commercially available in 1945 in the US. However, early influenza vaccines were relatively crude preparations of chick embryo allantoic fluid virus; they were frequently contaminated with bacterial endotoxin, which would evoke febrile reactions after vaccination and were contraindicated in children.
Purification of virus from infected chicken embryos using zonal ultracentrifugation has become the manufacturing process of choice for most marketed influenza vaccines for years and is still used currently. 20 Today, licensed influenza vaccines are tripartite, aiming to protect against two influenza A strains and one influenza B, as guided by the WHO. They exist in various forms, inactivated whole virus, split virus, subunit, or cold-adapted live virus vaccine (Table 2 18,21 −28 ). These seasonal vaccines have a protective efficacy in the range of 60−90%. 29 The vaccine industry also started working with other new modalities recently, including new adjuvant, reverse genetics techniques, recombinant DNA, vector-based vaccines, synthetic peptide vaccines and universal influenza vaccines targeting common epitopes. 30 Although the influenza vaccine had been used for 60 years, it never worked in pandemics until 2009. For the first time, a vaccine against a pandemic strain of influenza became available before the on set of winter, a time when lower temperatures and humidity allow the virus to spread more easily.
Pandemic Influenza A (H1N1) 2009 Vaccination in Taiwan
Taiwan has been implementing its annual seasonal influenza vaccination program for over a decade. In response to the pandemic, the new influenza A (H1N1) vaccine has been included in the program since November 1 st , 2009, along with the routine seasonal influenza vaccines. However, due to the limited supplies of influenza vaccine, Taiwan's Advisory Committee on Immunization Practices announced a pandemic influenza A (H1N1) vaccine priority list in late August of 2009. The top-listed groups included homeless people affected by Typhoon Morakot, health care and public health personnel, pregnant women, preschool children aged between 1 through 6 years, people with major illness/injury (aged 7 years and older), elementary school students (aged 7 through 12 years) and junior high school students (aged 13 through 15 years). 31 The pandemic H1N1 vaccination campaign in Taiwan used two types of vaccine: AdimFlu-S (unadjuvanted H1N1v; Adimmune, Taichung, Taiwan) and Focetria (MF59 adjuvanted H1N1v; Novartis International AG, Basel, Switzerland). As of March 2 nd , 2010, 5.12 million and 0.53 million doses of AdimFlu-S and Focetria had been administrated, respectively.
Debate on Pandemic Influenza A (H1N1) 2009 Vaccine in Taiwan
The massive vaccination program for pandemic influenza A (H1N1) 2009 in Taiwan was disturbed by an unfounded public fear about possible adverse events following immunization. Theoretically, the safety profile of such an emergent pandemic vaccine will likely be less certain than that of previously released influenza vaccines. As such, the safety of this vaccine will need to be closely monitored. According to the database of the Taiwan awareness survey between January 5 th and January 6 th , 2010 and an H1N1 vaccination survey for people aged 18 and above between January 7 and January 9, 2010. Approximately 40% of people in Taiwan indicated that they had decided against vaccination because of recent reports concerning vaccine adverse events. 35 Meanwhile, celebrities around the world were denouncing it, proudly proclaiming that they would not give it to their H1N1-vulnerable children, and many others followed their advice. The Internet has also fueled rumors about the vaccine, ranging from the simply false ("It hasn't been tested on humans") to the paranoid ("It's a WHO-led plot to depopulate the world"). 36 The Internet plays a large role in disseminating anti-vaccination information. Anti-vaccination protestors make postmodern arguments that reject biomedical and scientific facts in favor of their own interpretations. Provaccination advocates who focus on correcting misinformation reduce the controversy to merely an educational problem; however, these postmodern discourses must be acknowledged in order to begin a dialogue. 37 The first suspected vaccine-related death in children has also been proved to be caused by parvovirus B19 infection. The H1N1 vaccination coverage rate is the highest among students from first through third grade who have received the first of the two H1N1 vaccine doses (86.1%), followed by healthcare personnel (82%) and students from fourth through sixth grade (76.6%). 35 The overall coverage rate is around 70% in high school students. The numbers of school closures, and outpatient and emergency room visits for influenza-like illness declined after the implementation of H1N1 vaccination in high school students. 38,39
Social Impacts After Vaccination
The most common adverse effects of novel swine influenza vaccinations in children were pain or swelling at the injection site, fever and irritability. 33, 34 Many reported adverse events following the immunization of the pandemic influenza A (H1N1) 2009 vaccine in Taiwan during the vaccination campaign have been proved irrelevant to vaccines but psychogenic in nature. DSM-IV subsumes this condition under the rubric of "Somatoform disorders" and within the subcategory "Conversion disorder". 40 When vaccines are administered to groups, the physical reactions of the recipients may be similar, causing a form of mass reaction, the mechanism for which is the same as that for mass reactions from other causes. These phenomena have been categorized as "mass sociogenic illness", 41 and have been defined as the collective occurrence of a constellation of symptoms suggestive of organic illness, but without an identified cause in a group of people with shared beliefs about the cause of the symptoms. 42 
Where Are We Going?
On the basis of the historical interpretations of the waves of impact during the 1918 pandemic, some have speculated that this current 2009 H1N1 virus has the potential to become more virulent. 43 The current pandemic has killed 41 Taiwanese and made 908 people seriously ill between April, 2009 and February, 2010. The government has spent approximately NT$3 billion on buying 15 million vaccine doses and on running the 3,000 clinics for vaccination administration to the public. A total of 5.64 million vaccine doses were used to immunize 25 percent of the population among which 75 percent were aged under 18. 44 Moreover, the recent decision by the WHO to include the pandemic influenza A (H1N1) virus in the composition of the 2010 northern hemisphere influenza vaccine and its calling of an expert meeting on February 23 rd , 2010 signaled that the peak of the H1N1 pandemic had come to a close. 45 Further, according to the surveillance data collected by the Taiwan Centers for Disease Control, no new local outbreak of H1N1 infection occurred during the Chinese New Year holiday, demonstrating that the implementation of relevant disease control policies has effectively stopped the spread of the virus.
Conclusions
For the past nearly 40 years, scientists have been warning that an influenza pandemic on the order of the 1918 Spanish flu could strike at any moment. They imagined the perpetrator would emerge in Asia, and worried that the avian influenza strain H5N1 might be it. However, the pandemic in 2009 looks nothing like previous speculations. Not only did it begin in North America, but the swine virus behind it was a novel form of an H1N1 strain already circulating in humans. Although the new H1N1 virus is unusually dangerous for the young and for pregnant women, it causes a disease not more severe than seasonal influenza in most otherwise healthy people. Will the next pandemic be as mild as the recent one? Nobody knows. Vaccination is still the most effective way to block pandemic influenza, according to the domestic epidemiological surveillance data. It might not be a matter of "whether" but "when" the next pandemic comes. Therefore, the global community must recognize the economic, security, and health threats posed by the next influenza pandemic and invest accordingly. Health authorities and researchers should also check their preparedness according to the lessons learned from the 2009 pandemic.
